EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impact of racialization on neuroimaging and plasma biomarkers of Alzheimer's disease

Alexandra Gogola iD, Xuemei Zeng, Lilcelia A Williams, Theresa Chapple-McGruder, Anum Saeed, Brian J Lopresti, Beth Snitz, Dana Tudorascu, Davneet Minhas, Milos D Ikonomovic, Julia Kofler, Cristy Matan und 8 weitere

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.70463 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Alexandra Gogola und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers, Neuroimaging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Alzheimer's Association 2021 Zenith Award, Hjärnfonden, Sweden, Swedish Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Given the predominance of imaging and plasma biomarkers in Alzheimer's disease observational studies and clinical trials, it is critical to understand the differences between these biomarkers across racialized groups. METHODS A total of 260 older adults without dementia racialized as Black and/or African American (AA) and non‐Hispanic white (NHW), ranging in age from 50 to 90 years (68.8 ± 9.1 years), were evaluated for differences in plasma amyloid‐β (Aβ) 42/Aβ40, p‐tau181, p‐tau217, p‐tau231, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) as well as Aβ positron emission tomography (PET) and magnetic resonance (MR) imaging‐derived cortical thickness using Mann–Whitney U tests and analysis of covariance (ANCOVA). RESULTS Both Mann–Whitney tests and ANCOVA found significant differences between groups racialized as AA or NWH with respect to global 11 [C]‐Pittsburgh Compound B (PiB) standardized uptake value ratio (SUVR), cortical thickness values, p‐tau181, and p‐tau231 values ( p < 0.05). DISCUSSION Racialization should be given more consideration in AD clinical research, particularly when biomarker results are used for inclusion or exclusion criteria for clinical trials and qualification in clinical practice. Highlights Global 11 [C]‐Pittsburgh compound B (PiB) standardized uptake value ratio (SUVR), cortical thickness, p‐tau181, and p‐tau231 differed between groups Differences were unaffected by age, sex, apolipoprotein E *4 (APOE*4), education, and Mini‐Mental State Examination (MMSE) score Racialization needs more consideration in Alzheimer's disease clinical research Additional work is needed to understand the sources of biomarker differences

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseBiomarkersNeuroimagingAgedAged, 80 and overFemaleHumansMaleMiddle AgedAmyloid beta-PeptidesBlack or African AmericanBrainMagnetic Resonance ImagingNeurofilament ProteinsPositron-Emission Tomographytau ProteinsWhite

Stichwörter der Autor:innen

Alzheimer's diseaseCoBRA projectheart score studyimaging biomarkersplasma biomarkersracialization

Substanzen

Amyloid beta-PeptidesBiomarkersNeurofilament Proteinstau Proteins

Autor:innen und Institutionen

  • Department of Radiology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Department Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Alexandra Gogola

Förderung

  • Alzheimer's Association 2021 Zenith Award
  • Hjärnfonden, Sweden
  • Swedish Research Council
  • NIA NIH HHS
  • NIH HHS
  • the European Union Joint Program for Neurodegenerative Disorders
  • the Swedish Alzheimer Foundation
  • the European Union's Horizon Europe research and innovation programme

Zitieren

APA

Gogola, A., Zeng, X., Williams, L. A., Chapple-McGruder, T., Saeed, A., Lopresti, B. J., Snitz, B., Tudorascu, D., Minhas, D., Ikonomovic, M. D., Kofler, J., Matan, C., Pascoal, T. A., Aizenstein, H., Zetterberg, H., Blennow, K., Lopez, O., Villemagne, V. L., Karikari, T. K., & Cohen, A. D. (2025). Impact of racialization on neuroimaging and plasma biomarkers of Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70463

Vancouver

Gogola A, Zeng X, Williams LA, Chapple-McGruder T, Saeed A, Lopresti BJ, et al. Impact of racialization on neuroimaging and plasma biomarkers of Alzheimer's disease. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70463

BibTeX
@article{Gogola2025,
  author = {Gogola, Alexandra and Zeng, Xuemei and Williams, Lilcelia A and Chapple-McGruder, Theresa and Saeed, Anum and Lopresti, Brian J and Snitz, Beth and Tudorascu, Dana and Minhas, Davneet and Ikonomovic, Milos D and Kofler, Julia and Matan, Cristy and Pascoal, Tharick A and Aizenstein, Howard and Zetterberg, Henrik and Blennow, Kaj and Lopez, Oscar and Villemagne, Victor L and Karikari, Thomas K and Cohen, Ann D},
  title = {Impact of racialization on neuroimaging and plasma biomarkers of Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.70463}
}
Kostenlos starten →